A comprehensive analysis of cost of an active surveillance cohort compared to radical prostatectomy as primary treatment for prostate cancer

Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS‐JAPAN study

“…However, clinical data used in the mathematical models are hypothetical 8,10 and may deviate from data of actual clinical settings. Moreover, because EHR are used in the healthcare systems of specific regions, the generalizability of studies using EHR 11,15,16 is hindered by differing clinical practices, local populations, and demographics of individuals in the insurance systems. In this study, we performed a cost analysis using data from the J-CAP 14 study (a nationwide observational study reflecting recent trends in Japan) and the PRIAS-JAPAN study (a prospective observational study of the Japanese AS cohort).…”